 SAN DIEGO, Aug. 11, 2021 PRNewswire -- Evofem Biosciences, Inc., NASDAQ: EVFM Evofem or the Company, today reported financial results for the three- and six-month periods ended June 30, 2021. We are pleased to show strong and sustainable growth in Phexxi prescriptions and dispensed units in the second quarter. 